About
Radix Management
Radix BioSolutions Management
The Radix BioSolutions management team is composed of experienced scientists, business and operations talent. They are backed by a dedicated group of individuals, principally scientists by training, who are focused on applying the groundbreaking multiplexing capabilities of xMAP technology to enhance the research capabilities of Radix BioSolutions customers.
The Radix BioSolutions Team is led by:
Kerry Oliver, Ph.D. — President
Dr. Oliver received his Ph.D. in immunology from UT Southwestern in Dallas under the direction of Dr. Ellen Vitetta. After postdoctoral training at the NIH in pharmacology, Kerry spent three years in drug discovery at Pfizer in the immunology group. In the spring 1997, Kerry joined the R&D biology group at Luminex, and in late 2001 he started Radix BioSolutions which immediately became a Luminex partner that focuses on satisfying unmet customer needs with custom molecular and immunoassay development and manufacturing.
Christy Weiss — Vice President, Operations
Christy received her degree in Biology and Chemistry from West Texas A&M in Canyon Texas. She began work as a technician at Inland Laboratories. As Luminex was developing out of Inland Laboratories, Christy became one of the earliest Luminex employees. During her tenure with Luminex, Christy performed many roles. She established the customer support department, developed training classes for Luminex end users and provided software and documentation review for all Luminex product launches. In 2001, along with her business partners, Christy opened the doors to Radix BioSolutions in order to better meet the custom assay needs of Luminex customers. At Radix BioSolutions Christy is focused on providing custom solutions with superior service.
Dr. Kodumudi Venkat Venkateswaran — Vice President, Research and Business Development
Dr. Venkateswaran's research interests include advanced detection of biothreat agents, technology development for drug discovery, molecular and personalized medicine. He received his Ph.D. in Biochemistry/Immunology from Indian Institute of Science (IISc), Bangalore India. He worked as a scientist at Defense Research & Development Organization in India for more than 10 years in the areas of microbiology and toxicology. He did Post Doctoral Research Fellowship at University of California San Francisco (UCSF) in the Department of Laboratory Medicine for 3 years, in the area of transfusion medicine. He worked at University of California Lawrence Livermore National Laboratory (LLNL), Livermore, CA for 8 years and was the Advanced Diagnostics Group Leader at LLNL. His research projects at LLNL included biodetection instrumentation and advanced diagnostic methods design, development and validation. He pioneered the multiplex biothreat test development and participated in a number of government projects in the evaluation of various biodetection technologies. He constantly serves as a reviewer for the National Institutes of Health (National Institute of Allergy and Infectious Diseases) in the Special Emphasis Panels. He has more than 30 scientific publications and over 6 patents (US and International). He won a number of awards for his scientific contributions including "R & D 100 Award". He was invited speaker in a number of national and international conferences. He has also organized a number of scientific workshops and events. At Radix BioSolutions, Venkat leads our biothreat and infectious disease development efforts, among others.
Erik Miller, MBA, BS Pharm. — Vice President, Business Development and Marketing
Erik received his BS Pharmacy degree from the University of Iowa, College of Pharmacy. He began work in the doctoral program at the U of Iowa, College of Medicine, Department of Pharmacology and published work regarding cell signaling and applied pharmaceutics. Erik shifted his focus to business aspects of pharmaceuticals and took a sales position with the Upjohn Company. He then completed his MBA at the University of North Carolina, Chapel Hill. Next he has focused on improving operational efficiencies with Ernst and Young Health Care consulting and Product Marketing and Management. With Biosite Diagnostics, he launched the Triage Microbiology line of products. Erik moved to Safety Syringes, Inc. and helped formulate their strategy to meet the demands of the pharmaceutical industry regarding minimizing potential for needlesticks. This led to major launches of important safety integrated products such as Pfizer's Fragmin, Amgen's Aranesp and Merck's Gardasil. Erik moved to Luminex with whom he managed key marketing functions on the research side of their business as well as direct management of important Luminex partners. His degree of customer focus has found a home at Radix BioSolutions where he helps design programs and processes to maximize the potential of xMAP technology on a custom basis.